AI Policy & Regulation
FDA Launches Elsa 4.0 and HALO for AI-Enhanced Reviews
The US Food and Drug Administration integrates generative AI to synthesize data across 40 siloed systems.
Digital displays showing interconnected data nodes and medical information in a modern professional setting.
Photo: Kronos News
The US Food and Drug Administration (FDA) officially upgraded its artificial intelligence infrastructure on May 30, 2026 [1]. The agency launched Elsa 4.0 and the Harmonized AI and Lifecycle Operations (HALO) for Data platform to modernize its regulatory framework [1]. These tools shift generative AI from a peripheral utility to a core interface for synthesizing complex data [1].
Elsa 4.0 and HALO allow reviewers to query information across more than 40 previously siloed systems [1]. This technological integration aims to accelerate the review process for new therapies and improve regulatory science [1]. The platforms prioritize data lifecycle operations to ensure consistency and speed in official evaluations [1].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
The risk level is set to high because the report relies on a single source domain (jmir.org), failing the checklist requirement for at least three independent domains.
Sources
Related stories
View all
Topics
About the author
Kronos News Desk covers ai policy & regulation and editorial analysis for Kronos News.